Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04483947 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
A Phase 1 study of Non-alcoholic Steatohepatitis (NASH), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 16
- Study locations
NCT04483947: Completed Phase 1 study of Non-alcoholic Steatohepatitis (NASH), sponsored by AstraZeneca.
NCT04483947 is a Phase 1 study of Non-alcoholic Steatohepatitis (NASH) that has completed, run by AstraZeneca. The registered enrollment target is 74 participants, below the 192-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04483947, a Phase 1 study of Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carriers of the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M risk alleles.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD2693
Study Locations (16)
California
- Research Site - Chula Vista
- Research Site - La Mesa
- Research Site - Montclair
- Research Site - San Diego
Florida
- Research Site - Doral
- Research Site - Hialeah
- Research Site - Hialeah
- Research Site - Miami Lakes
Texas
- Research Site - Arlington
- Research Site - Dallas
- Research Site - San Antonio
- Research Site - San Antonio
Indiana
- Research Site - Indianapolis
North Carolina
- Research Site - Morehead City
Ohio
- Research Site - Columbus
Pennsylvania
- Research Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 1 |
What the finished NCT04483947 record still lists
NCT04483947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 192-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04483947 lists 16 locations in 7 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT04483947 about?
NCT04483947 is a clinical study titled "A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients". This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carri...
What is the current status of trial NCT04483947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2020-11-06. Estimated completion is 2023-12-18.
What conditions does trial NCT04483947 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT04483947?
The interventions under investigation include: Placebo (OTHER), AZD2693 (DRUG).
Who is sponsoring clinical trial NCT04483947?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04483947 being conducted?
This trial has 16 study locations across California, Florida, Indiana, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04483947's enrollment target sits among peer trials
74 12th of 16 higher than 5 of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
RECRUITING · Phase 1
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
ACTIVE NOT RECRUITING
-
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
ACTIVE NOT RECRUITING · NA
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI